Prosecution Insights
Last updated: November 04, 2026
Application No. 18/412,163

EXPANSION OF MEMORY NATURAL KILLER CELLS

Non-Final OA §102§112
Filed
Jan 12, 2024
Priority
Jul 15, 2021 — provisional 63/222,306 +1 more
Examiner
CHATTIN, AMY MARIE
Art Unit
1643
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Wugen Inc.
OA Round
1 (Non-Final)
71%
Grant Probability
Favorable
1-2
OA Rounds
11m
Est. Remaining
99%
With Interview

Examiner Intelligence

Grants 71% — above average
71%
Career Allowance Rate
40 granted / 56 resolved
+11.4% vs TC avg
Strong +46% interview lift
Without
With
+45.9%
Interview Lift
resolved cases with interview
Typical timeline
3y 9m
Avg Prosecution
38 currently pending
Career history
101
Total Applications
across all art units

Statute-Specific Performance

§101
3.9%
-36.1% vs TC avg
§103
31.9%
-8.1% vs TC avg
§102
18.8%
-21.2% vs TC avg
§112
32.5%
-7.5% vs TC avg
Black line = Tech Center average estimate • Based on career data from 56 resolved cases

Office Action

§102 §112
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Claims Status The Amendment filed on DATE is acknowledged in which claim(s) 2, 8, 10, 12-20, 23-26, 29, 31, 33-41 , 46-48, 51-57 was/were canceled by Applicant. Applicant’s election without traverse of Group I and the species of purified CIML NK cell priming agent of 18y15-12s, in the reply filed on 19Aug2026 is acknowledged. Claim(s) 42-45, 49-50 is/are withdrawn from further consideration pursuant to 37 CFR 1.142(b) as being drawn to a nonelected invention and/or species, there being no allowable generic or linking claim. Election was made without traverse in the reply filed on 19Aug2026. Claim(s) 1, 3-7, 9, 11, 21-22, 27-28, 30, 32 is/are presented for examination on the merits. Specification The use of trade name(s) or mark(s) used in commerce (e.g., FlowJo), has been noted in this application. The term should be accompanied by the generic terminology; furthermore the term should be capitalized wherever it appears or, where appropriate, include a proper symbol indicating use in commerce such as ™, SM , or ® following the term. Although the use of trade names and marks used in commerce (i.e., trademarks, service marks, certification marks, and collective marks) are permissible in patent applications, the proprietary nature of the marks should be respected and every effort made to prevent their use in any manner which might adversely affect their validity as commercial marks. The disclosure is objected to because of the following informalities: The number of digits for paragraph numbers (e.g., [0001], [00288]) should be consistent throughout. Appropriate correction is required. Claim Interpretation Claim(s) 1, 3-7, 9, 11, 21 recite “…a population of purified cytokine-induced memory-like natural killer cells (CIML NK cells) produced by …” in lines 1-2 of claim 1. The instant specification does not define CIML NK cells. MPEP 2112.01(I) provides “Where the claimed and prior art … are produced by identical or substantially identical processes, a prima facie case of either anticipation or obviousness has been established. In re Best, 562 F.2d 1252, 1255, 195 USPQ 430, 433 (CCPA 1977)…”. Therefore, the broadest reasonable interpretation (BRI) is considered to be that any prior art teaching of the sequential steps (e.g., a) and b)) of instant claim 1 are considered to teach the population of purified CIML NK cells of instant claim 1. Claim(s) 1, 3-7, 9, 11, 21 recite “…sequentially…” in line 2 of claim 1. The instant specification does not define ‘sequentially’. Therefore, the broadest reasonable interpretation (BRI) is considered to be that any prior art teaching of that the steps are performed sequentially (e.g., in any order). Claim Rejections - 35 USC § 112(b) The following is a quotation of the first paragraph of 35 U.S.C. 112(a): (a) IN GENERAL.—The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor or joint inventor of carrying out the invention. The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. Claim(s) 21 is/are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. Regarding claim(s) 21, the phrase "optionally" in line “d)” renders the claim indefinite because it is unclear whether the limitation(s) following the phrase are part of the claimed invention. See MPEP § 2173.05(h)(II). It is unclear if the limitation(s) following the phrase are limitation(s) or merely provided as an example. For the purposes of compact prosecution, the limitations following the phrase are not considered part of the claimed invention. This rejection may be overcome by amending claim(s) 21 to remove “optional” limitations and/or the phrase “optionally”. Claim Rejections - 35 USC § 102 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention. (a)(2) the claimed invention was described in a patent issued under section 151, or in an application for patent published or deemed published under section 122(b), in which the patent or application, as the case may be, names another inventor and was effectively filed before the effective filing date of the claimed invention. The text of those sections of Title 35, U.S. Code not included in this action can be found in a prior Office action. Claim(s) 1, 3-7, 9, 21-22, 27-28, 30 is/are rejected under 35 U.S.C. 102(a)(1) and 102(a)(2) as being anticipated by US 2021/0137981 A1 (published 13May2021, effective filing date 21Jun2019; hereinafter “US981”), as evidenced by Balkhi et al. (Front. Immunol. 16:1574742, 2025; hereinafter “Balkhi”). Regarding instant claim(s) 1, 3, 5-7, 9, 22, 27-28, US981 teaches a population of NK cells (e.g., CIML NK cells, see claim interpretation for details) wherein purified NK cells are stimulated (e.g., primed) with 18t15-12s (e.g., comprising IL18, IL15, IL12) and then expanded with 7t15-21s (e.g., sequentially) [e.g., ¶ 0052, 0056; figs. 20, 24; example 20]. US981 further teaches the NK cells were isolated (e.g., purified, enriched) from blood bank samples (e.g., donor blood), and CD56+ (e.g., positive selection) [e.g., ¶ 0377]. Regarding claim(s) 4, the NK cells as taught by US981 (see above) are the same as the NK cells manufactured as required by claim(s) 4. Claim 4 is a product by process type claim and MPEP 2113(I) provides “[E]ven though product-by-process claims are limited by and defined by the process, determination of patentability is based on the product itself. The patentability of a product does not depend on its method of production. If the product in the product-by-process claim is the same as or obvious from a product of the prior art, the claim is unpatentable even though the prior product was made by a different process." In re Thorpe, 777 F.2d 695, 698, 227 USPQ 964, 966 (Fed. Cir. 1985)”. The differentiation of NK cells from progenitor cells (e.g., instant claim 4) would not lead one of ordinary skill in the art to reasonably expect the manufacture of a patentably distinct product from that of instant claim 1. Therefore, the product by process claim 4 is not considered patentably distinct from the product of instant claim 1, which is taught by US981 (see above for details). Regarding instant claim(s) 21, US981 teaches the NK cell additionally comprises a CAR [e.g., ¶ 0011]. All CARs (e.g., first-fifth generation) comprise an extracellular antigen binding domain (e.g., binds antigen on target cell), a hinge, a transmembrane domain, and a cytoplasmic signaling domain (e.g., intracellular domain), and second-fifth generation CARs further comprise one or more costimulatory domains, as evidenced by Balkhi [e.g., “3 Construction of CAR-NK cells”; fig. 1]. Allowable Subject Matter Claim(s) 11 and 32 is/are objected to as being dependent upon a rejected base claim, but would be allowable if rewritten in independent form including all of the limitations of the base claim and any intervening claims. Specifically, the step comprising expansion of NK cells in the presence of 7t15-21s and ATF1 (activating transcription factor 1) was found to nonobvious over the prior art. Briefly, the expansion of NK cells in the presence of 7t15-21s was known in the art at the time of filing (e.g., see 102 rejection above for details). However, no prior art was found teaching ATF1 for NK cell expansion, nor was any rationale found in the art that would lead one of ordinary skill in the art to arrive at the instant invention step comprising expanding NK cells in the presence of ATF1 and 7t15-21s. Therefore, instant claim(s) 11 and 32 are considered non-obvious in view of the closest prior art. Conclusion No claims are currently allowed. Any inquiry concerning this communication or earlier communications from the examiner should be directed to AMY M CHATTIN whose telephone number is (571)270-0646. The examiner can normally be reached T-F 0600-1600 PST. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Julie Wu can be reached at (571) 272-5205. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /AMY M. CHATTIN/Examiner, Art Unit 1643 /GARY B NICKOL/Primary Examiner, Art Unit 1643
Read full office action

Prosecution Timeline

Jan 12, 2024
Application Filed
Oct 27, 2026
Non-Final Rejection mailed — §102, §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12782357
ANTIBODIES THAT BIND TO LRP5 PROTEINS AND METHODS OF USE
4y 8m to grant Granted Nov 03, 2026
Patent 12753229
COMPOSITIONS AND METHODS FOR MODULATING FLRT3 MEDIATED SIGNAL TRANSDUCTION
3y 9m to grant Granted Oct 06, 2026
Patent 12734239
UNIVERSAL ANTIGEN PRESENTING CELLS AND USES THEREOF
6y 0m to grant Granted Sep 15, 2026
Patent 12714749
PHARMACEUTICAL COMPOSITION CONTAINING EXOSOME AND PREPARATION METHOD THEREOF
3y 1m to grant Granted Aug 25, 2026
Patent 12709639
METHODS OF ADMINISTERING CHIMERIC ANTIGEN RECEPTOR IMMUNOTHERAPY
2y 9m to grant Granted Aug 18, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
71%
Grant Probability
99%
With Interview (+45.9%)
3y 9m (~11m remaining)
Median Time to Grant
Low
PTA Risk
Based on 56 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month